INTRODUCTION
Mycosis fungoides (MF) is a neoplasm of the immune system. It is characterized by neoplastic T lymphocytes that home to the skin, producing characteristic lesions. Initially, various erythematous patches develop. These may be chronic, existing for several years until they become plaques, nodules, erythroderma, or tumors. It is often difficult to diagnose MF in its early phase, either because of overlapping features with benign inflammatory dermatoses or because of complex and occasionally conflicting clinicopathological findings 1 . Clinicopathological variants of MF include hyperkeratotic-, bullous-, hypopigmented-, hyperpigmented-, porokeratotic-, granulomatous-, folliculotropic-, pustular-, verrucous-, erythrodermatous-, and pagetoid reticulosis 2 .
Pityriasis lichenoides (PL)-like MF is a rare subtype of MF that involves the same skin lesions as PL. Histologically, PL-like MF has the findings of MF 3 . In this study, we investigated the clinical, pathological, and immunohistochemical features and treatment of PL-like MF.
MATERIALS AND METHODS

Patients
Fifteen patients, who had a clinical features of erythematous scaly, crusted macules, papules, or plaques (PL-like skin lesions) and histopathological features of MF according to the diagnostic criteria of the European Organization for Research and Treatment of Cancer (EORTC) 4 were enrolled in this study. We excluded any patients who was not shown obvious histopathological features of MF. This study was approved by the institutional review board of Kosin University Gospel Hospital (IRB no. 91961-ABG-15-031). 
Clinical assessment
We collected data regarding patient age, gender, disease duration, skin lesion distribution and shape, symptoms, TNM stage, and treatments. Clinical photographs were taken at every follow-up visit with the same digital camera (α350; Sony, Tokyo, Japan), in the same position, and under controlled lighting conditions. Two independent dermatologists assessed patient responses to phototherapy based on the photographs. Their evaluation defined the clinical response as complete improvement (95% or greater clinical improvement); partial improvement (50% or greater clinical improvement); or no response (＜50% clinical improvement). After treatment was complete, patients were followed every one to two months to detect recurrence.
Histopathological, immunohistochemical, and molecular evaluations
Biopsies were conducted on the PL-like lesions. Evaluation was based on the early MF findings of Pimpinelli et al. 5 Typical MF and PL findings were observed. Paraffin-embedded tissue sections were stained using monoclonal antibodies against CD3, CD4, CD8, and CD30. In order to evaluate the gene rearrangement of the T cell gamma receptor, DNA was separated from 10 paraffin-embedded tissues for polymerase chain reaction (PCR).
RESULTS
Clinical manifestations (Fig. 1 Immunohistochemical findings and molecular biological evaluation (Fig. 3 , Table 3 )
In most cases, the atypical lymphocytes expressed the CD3 antigen. In 12 cases (80.0%), CD8-positive T cells were more frequently observed than CD4-positive T cells. Two (patient 7, 10) of these 12 cases showed predominance of CD8-positive T cells in the dermis compared to CD4-positive T cells, and predominance of CD4-positive T cells in the epidermis compared to CD8-positive T cells. Thirteen patients had CD30-negativity of the lesion. PCR was used for T cell receptor γ gene rearrangement in 10 patients. Monoclonal findings were confirmed in eight patients (80.0%).
Treatments and courses (Table 1) Narrowband ultraviolet B (NBUVB) and psoralen+ultra-violet B (PUVA) therapy was performed in 10 and 3 patients, respectively. All patients who received PUVA therapy showed complete improvement. Among them, one patient (patient 2) developed classic MF 10 years later and then had full improvement after NBUVB therapy. All patients treated with NBUVB also experienced full improvement. The follow-up period after diagnosis ranged from five months to 12 years, with a mean of 2.9 years. Among patients for whom follow up data were available, at the final follow up, eight of 10 patients (80.0%) in the NBUVB group remained relapse-free. The malignant potential of PL is debated. There are some reports of "atypical PLEVA" with transformation to MF 8, 9 .
Rivers et al. 10 reported that of 13 patients initially diagnosed with PL, six were ultimately diagnosed with MF. It is likely that these cases can be explained by misdiagnosis 
PL: pityriasis lichenoides, MF: mycosis fungoides, TCR: T-cell receptor, ND: not done. Dereure et al. 11 found that 65% of 20 PLEVA patients had T cell clones. Massone et al. 12 found that 50%∼60% of MF patients had T-cell receptor (TCR) gene rearrangements. This suggests that TCR is not a very useful method of differentially diagnosing PL and PL-like MF. In this study, 10 patients underwent the tests, and 80% of PL-like MF cases were verified to exhibit monoclonality. MF treatments are determined based on the presence of systemic conditions, age, and disease course. Skin-directed therapies, including phototherapy (PUVA, NBUVB) and topical chemotherapeutic agents (mechlorethamine, nitrogen mustard, carmustine), are known to be effective, safe, and convenient, particularly in early MF 8 . Also, UVA1 has a sensitive effect on neoplastic cells by increasing production of tumor necrosis factor-α, and it might be an effective treatment for MF 13 .
Ozawa et al. 14 found that NBUVB induces T cell apoptosis in inflammatory skin lesions and expresses cell toxicity. Based on this mechanism, NBUVB has been used to treat various inflammatory skin diseases, including psoriasis, atopic dermatitis, and lichen planus, which all involve T cell infiltration into the epidermis and dermis. NBUVB was also reported to inhibit T cell neoplastic proliferation and penetration into the upper dermis and effectively treated MF in Asian populations 15, 16 . Therefore, NBUVB can also be used for PL-like MF, which develops mostly in the early stage of MF and demonstrates neoplastic T cell infiltration into the epidermis and the upper dermis. PUVA is therapeutic because it induces tumor cell apoptosis and DNA damage, suppresses keratinocyte cytokine production, and depletes Langerhans cells 17 . It has been widely used as an effective first-line treatment of early MF and as a supplementary treatment for advanced MF 18 .
There are only a few studies that have addressed PL-like MF phototherapy. Most of these studies involved combination therapy; therefore, the effects of phototherapy alone are not fully understood. Wang et al. 19 reported one case of complete response using topical corticosteroids. de Unamuno Bustos et al. 6 reported three cases of combination therapy that included PUVA and one case of PUVA therapy alone. They found that there was a partial response in the three cases of combination therapy, and a complete response in the PUVA-only case. One of the authors of this study reported cases of successful treatment of PL-like MF using PUVA 3 . Including previous study data, three PUVA therapy patients and 10 NBUVB therapy patients demonstrated full improvement in this study. These findings suggest that phototherapy is sufficient for the treatment of PL-like MF. The mean follow-up period after diagnosis was 2.9 years. There have been cases of recurrence in one PUVA case and two NBUVB cases. According to long term follow-up data of this study, patients had favorable prognoses similar to other reports 3, 6, 19 .
PL-like MF is a rare type of early MF that mainly develops in young patients and some adult patients and has a favorable prognosis. Its presentation is similar to that of PL. de Unamuno Bustos et al. 6 also reported four adult PL-like MF patients. Also, there is high possibility of misdiagnosis, so there could be more cases than reported. Therefore, a clear understanding of the diagnosis and follow-up are needed. Histological findings of both MF and PL are present in PL-like MF. Based on immunohistochemistry, there are more CD8-positive cells than CD4-positive cells in PL-like MF, characterized by a CD8+ cytotoxic pheno-type, similar to the findings in PLEVA. This study involved Asian patients, who have not been studied extensively in this field. We observed that the disease occurred in adults and that NBUVB can be used for PL-like MF due to its inhibition of T cell neoplastic proliferation and penetration into the upper dermis 16 . We also observed the favorable prognosis of this variant of MF by analyzing long-term follow-up data. PL-like MF lesions are easily misdiagnosed or confused with other papular skin diseases. Therefore, skin biopsy is required for accurate diagnosis.
